Clinical trials: Tumor Skin, open to volunteers
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy
The main goal of this study is to investigate the effectiveness and safety of chemotherapy agents in the treatment of participants with BPDCN and to provide comparator arm data to the prospective ELZONRIS registry study…
- Trial name
- NCT07785180
- Testing
- Chemotherapy
- Where
- 67 sites in Denmark, France and 9 more
- Volunteers
- 140 people
- Sponsor
- Stemline Therapeutics, Inc.
Solid Cancer, Gastric (Cardia, Body) Cancer
Impact of CES1 Genotype on Capecitabine Exposure in Cancer Patients
In this study, the drug capecitabine is investigated. Capecitabine is commonly used to treat breast, colon, and stomach cancers. Capecitabine is taken in tablet form.
- Conditions
- Solid Cancer, Gastric (Cardia, Body) Cancer, Esophageal Cancer, Colorectal Cancer (CRC)
- Trial name
- ESCAPE (NCT07114627)
- Testing
- Blood sampling for pharmacokinetics
- Where
- Netherlands
- Volunteers
- 66 people
- Sponsor
- Erasmus Medical Center
Breast Cancer
Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer
Capecitabine combined with pyrotinib is the standard protocol for HR+/HER2+ advanced breast cancer after trastuzumab failure, but the incidence of grade 3 hand-foot-syndrome was 16.4%.
- Trial name
- NCT04646759
- Testing
- Fulvestrant combined with Pyrotinib, Capecitabine combined with Pyrotinib
- Where
- China
- Volunteers
- 516 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Early Breast Cancer, Ductal Breast Carcinoma In Situ
Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
Hypofractionated breast radiotherapy with concomitant tumor bed boost for early breast cancer or ductal breast carcinoma in situ after partial mastectomy
- Trial name
- HFCBB (NCT06984250)
- Testing
- Hypofractionated Radiation Therapy
- Where
- 2 sites in Taiwan
- Volunteers
- 315 people
- Sponsor
- National Taiwan University Hospital
Breast Cancer, Perimenopause
AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast Cancer
This study is a prospective observational cohort study aimed at developing a clinical model based on dynamic changes in anti-Müllerian hormone (AMH) to predict ovarian reserve in perimenopausal women with hormone…
- Conditions
- Breast Cancer, Perimenopause, Ovarian Reserve
- Trial name
- NCT07497191
- Volunteers
- 300 people
- Sponsor
- Shengjing Hospital
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Video-Conferenced Stress Management and Relaxation Training (VSMART) For Alabama Breast Cancer Survivors
In a sample of Alabama breast cancer survivors, the proposed study tests the feasibility and acceptability of a stress management program that has been shown to improve health and wellbeing in a general population of patients…
- Trial name
- VSMART (NCT06924788)
- Testing
- Video-Conferenced Stress Management and Relaxation Training (VSMART)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Alabama at Birmingham
Pancreas Cancer, Pancreatitis
Pancreas Registry and High Risk Registry
The purpose of this study is to establish a registry of patients with pancreatic diseases. Patients included in the registry may include those with: pancreatic cancer, precancerous lesions of the pancreas, inflammatory lesions of…
- Conditions
- Pancreas Cancer, Pancreatitis, Chronic Pancreatitis, Pancreatic Cyst
- Trial name
- NCT02775461
- Where
- 2 sites in United States
- Volunteers
- 1,368 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Actinic Keratosis (AK)
An Open-Label Pharmacokinetic Study for Patients With Actinic Keratosis on the Upper Extremities or the Face
The research study will evaluate how the body absorbs and reacts to reformulated Levulan Kerastick when applied to actinic keratosis lesions (AKs) on the skin of the forearms or face followed by photodynamic therapy (PDT), a…
- Trial name
- NCT07729579
- Testing
- Investigational drug, Photodynamic therapy
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Hepatocellular Carcinoma, Renal Cell Carcinoma
Study of ACC-1898 in Adult Participants With Advanced Solid Tumors
This is a research study of an experimental drug called ACC-1898. ACC-1898 is an oral tyrosine kinase inhibitor (TKI) that blocks several proteins kinases which may help cancer cells grow and spread.
- Conditions
- Hepatocellular Carcinoma, Renal Cell Carcinoma, Thyroid Carcinoma, Medullary, Thyroid Carcinoma Primary Differentiated
- Trial name
- NCT07252661
- Testing
- ACC-1898
- Volunteers
- 40 people
- Sponsor
- AccSalus Biosciences, Inc.
Solid Tumor Malignancy, Breast Cancer
Ataraxis Real-World Clinical Outcomes Registry Linking AI-Based Pathology Scores to Patient Outcomes
The ARC Registry is a large-scale, multi-site, prospective, observational registry. All patients with a solid tumor malignancy who receive Ataraxis testing as part of routine clinical care are eligible for enrollment, which will…
- Trial name
- ARC (NCT07706842)
- Testing
- Ataraxis testing
- Volunteers
- 1,000 people
- Sponsor
- Ataraxis AI, Inc.
Sezary Syndrome, Ichthyosis, Lamellar
Lymphocyte Phenotype of Autosomal Recessive Congenital Ichthyoses Mutated NIPAL4 (Nipal4-nEDD)
Autosomal recessive congenital ichthyoses (ARCI) are monogenic diseases of cornification that correspond to a diffuse abnormality (affecting the entire integument) of epidermal differentiation and therefore of the skin barrier.
- Trial name
- NIPALYMPHO (NCT07477769)
- Testing
- blood sampling
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Breast Cancer, Triple Negative Breast Cancer
Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery
This single arm study aims to evaluate the efficacy and safety of a non-surgical approach, consisting of radiotherapy (RT) alone, for patients who have achieved a complete pathological response (pCR) following neoadjuvant…
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, HER2-positive Breast Cancer, Neoadjuvant Chemotherapy
- Trial name
- BETTY-CRASY (NCT06281210)
- Testing
- Omission of surgical treatment
- Where
- 2 sites in Italy
- Volunteers
- 77 people
- Sponsor
- European Institute of Oncology
Triple-negative Breast Cancer (TNBC)
Predicting Response to Immunochemotherapy in Early Triple Negative Breast Cancer
The goal of this clinical trial is to identify cellular and molecular determinants of response to neoadjuvant immunochemotherapy in women aged 18 or older with early-stage triple-negative breast cancer (TNBC).
- Trial name
- PRIME-TNBC (NCT07570524)
- Testing
- Additionnal breast biospy and blood sample
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Center Eugene Marquis
Breast Cancer, Neoadjuvant Therapy
Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy
Iparomlimab and Tuvonralimab Injection (QL1706) is a bifunctional combination antibody targeting both programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA-4).
- Conditions
- Breast Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitors, QL1706
- Trial name
- NCT07372079
- Testing
- QL1706 combined with Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
A Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological Maps
The goal of this observational study is to develop and validate an artificial intelligence (AI) model for predicting the risk of distant metastasis in patients with primary breast cancer.
- Trial name
- ARGUS project (NCT07244094)
- Testing
- Diagnostic Test: AI-Based Spatial Pathomic Analysis
- Where
- 4 sites in China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Breast Cancer, Metastatic Breast Cancer
Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches
MELODY is a prospective, single-arm phase II study introducing routine liquid-biopsy next-generation sequencing for patients with advanced or unresectable breast cancer in Ireland.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
- Trial name
- MELODY (NCT07893730)
- Testing
- Liquid biopsy next generation sequencing
- Volunteers
- 50 people
- Sponsor
- University College Cork
Breast Cancer, Exercise and Recovery
Research on the Development and Validation of Personalized Exercise Prescription System for Breast Cancer Patients Based on Large Language Models
The goal of this observational study is to develop and evaluate a large language model (LLM)-based decision support system for exercise prescription in breast cancer patients, aiming to provide personalized decision-making…
- Trial name
- NCT07767565
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Metastatic Breast Cancer With HER2 Positive
SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer
The goal of this clinical trial is to learn if SHR-A1811 combine with Pyrotinib is safe and tolerable for patients with HER2 positive breast cancer. It will also learn about the anti-tumor efficacy of this combination therapy.
- Trial name
- NCT07132242
- Testing
- SHR-A1811 4.0mg/kg, Pyrotinib 240mg, SHR-A1811 4.8mg/kg
- Volunteers
- 84 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Breast Cancer
Comparison of the Safety and Aesthetic Outcomes of a Novel Endoscopic-Assisted Breast-Conserving Surgery (SRRSHzb-EABCS) With Those of Conventional Breast-Conserving Surgery
This multicenter, open-label, prospective, randomized controlled study compares a novel endoscopy-assisted breast-conserving surgery technique (SRRSHzb-EABCS) with conventional open breast-conserving surgery (CBCS) in women with…
- Trial name
- ZACA001 (NCT07920094)
- Testing
- Endoscopy-assisted breast-conserving surgery (SRRSHzb-EABCS), Conventional open breast-conserving surgery (CBCS)
- Where
- 22 sites in China
- Volunteers
- 422 people
- Sponsor
- Sir Run Run Shaw Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.